Abstract:Abstract Acute lymphoblastic leukemia (ALL) is the most common cancer in children. While most cases of ALL arise from B-cell precursors, 15% originate from T cells in the thymus (T-ALL). With current treatments, survival rate is high, but relapse occurs in 15-20% of children. In addition, most treatments are highly toxic, with severe side effects. Approximately 10% of T-ALL patients have somatic gain-of-function mutations in IL7Rα gene, and 15-22% of ALL patients have mutations in NRAS or KRAS. Furthermore, Ras pathway mutations are responsible for 30%-50% of ALL relapse. Recently, our lab showed that mutations in human IL7Rα alone (c.731_732insTTGTCCCAC) or human NRAS alone (G13D) are not sufficient to induce T-ALL from primary cells. However, a combination of both causes severe T-ALL in mice. Treatment with inhibitors against IL7Rα and NRAS signaling led to prolonged survival in these mice. Our new data indicate that the correct ratio between IL7Rα and NRAS expression is necessary to generate T-ALL in mice. Using RAG-/- mice injected with primary thymocytes transduced with mutated IL7Rα and NRAS in the optimal sequence in a polycistronic vector led to fatal disease 3 weeks after injection. These mice showed a 30-fold increase of leukocytes in the blood, spleen, and thymus, 80-fold increase in the lymph nodes, and a 5-fold increase in spleen weight, all indications of severe T-ALL. There was no indication of disease progression in mice injected with either empty vector or wild-type IL7Rα and mutated NRAS. To identify the pathways involved in T-ALL by these mutations, we used mass spectrometry and RNA sequencing. Our analysis showed significant increases in the well-known antiapoptotic, B-cell lymphoma 2 (BCL-2), mRNA, and protein levels and a major decrease in the proapoptotic BCL-2 antagonist/killer 1 (BAK-1) protein levels. In this manner, combination of both IL7Rα and NRAS mutations resulted in high Bcl-2:Bak-1 ratio, supported also by Western blot analysis. In addition, we observed a significant increase in the protein cytokinesis midbody regulator citron kinase (Cit), potentially leading to increased thymocytes proliferation and driving T-ALL formation. Taken together, our lab developed a strong model to study T-ALL in mice, shedding light on novel pathways of oncogenesis and targets for better therapeutic development. Citation Format: Hila Winer, Gisele Rodrigues, Wenqing Li, Julie Hixon, Scott Durum. A combination of IL7Rα and NRAS mutations sheds light on the oncogenesis of T-cell acute lymphoblastic leukemia in a murine model [abstract]. In: Proceedings of the AACR Special Conference on the Advances in Pediatric Cancer Research; 2019 Sep 17-20; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Res 2020;80(14 Suppl):Abstract nr B57.

Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma

Oncogenic IL7R Gain-of-function Mutations in Childhood T-cell Acute Lymphoblastic Leukemia.

O023 Oncogenic IL-7R Gain-of-function Mutations in Childhood T-ALL

Identification of Genetic Alterations Associated with Mutant Il7ralpha in T-All

Mutations that collaborate with IL-7Ra signaling pathways to drive ALL

Abstract 2462: A Combination of IL7Rα and NRAS Mutations Up-Regulates Bcl-2 and Cmyc Levels Leading to Formation of T-cell Acute Lymphoblastic Leukemia

Abstract B47: Overexpression of TLX3 or HOXA9 in association mutant IL7Rα are sufficient to generate T-ALL in vivo

Overexpression of Htlx3 in Association with Mutant IL7Rα is Sufficient to Generate T-ALL in Vivo and to Transform Thymocytes in Vitro

Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice

A combination of IL7R alpha and NRAS mutations sheds light on the oncogenesis of T-cell acute lymphoblastic leukemia in a murine model

Abstract B57: A Combination of IL7Rα and NRAS Mutations Sheds Light on the Oncogenesis of T-cell Acute Lymphoblastic Leukemia in a Murine Model

UTX Inhibition As Selective Epigenetic Therapy Against TAL1-driven T-cell Acute Lymphoblastic Leukemia

Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?

An instructive role for Interleukin-7 receptor α in the development of human B-cell precursor leukemia

ID: 64: Targeting the IL-7R pathway in leukemia

Prognostic impact of IL7R mutations on acute myeloid leukemia

New Anti-Il-7rα Monoclonal Antibodies Show Efficacy Against T Cell Acute Lymphoblastic Leukemia in Pre-Clinical Models

Co-existence of IL7R High and SH2B3 Low Expression Distinguishes a Novel High-Risk Acute Lymphoblastic Leukemia with Ikaros Dysfunction

Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.

IL-7 Receptor Polymorphisms is Related to Signaling Strength Which is Associated with Autoimmune T Cells Activation in Multiple Sclerosis

Low IL7R Expression at Diagnosis Predicted Relapse in Adult Acute Myeloid Leukemia Patients With t(8;21)